Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3099725
Max Phase: Preclinical
Molecular Formula: C177H272N52O55
Molecular Weight: 4008.43
Molecule Type: Unknown
Associated Items:
ID: ALA3099725
Max Phase: Preclinical
Molecular Formula: C177H272N52O55
Molecular Weight: 4008.43
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)O[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C
Standard InChI: InChI=1S/C177H272N52O55/c1-16-88(10)138(182)167(277)212-112(26-17-18-60-178)171(281)228-66-24-32-127(228)165(275)209-109(52-57-134(243)244)144(254)201-91(13)170(280)227-65-23-31-126(227)164(274)197-80-132(240)203-107(51-56-133(241)242)149(259)223-123(78-137(249)250)155(265)200-90(12)143(253)225-125(82-231)172(282)229-67-25-33-128(229)166(276)210-111(54-59-136(247)248)151(261)208-110(53-58-135(245)246)152(262)214-115(69-85(4)5)157(267)222-122(77-131(181)239)162(272)206-104(28-20-62-194-175(186)187)147(257)217-118(73-96-38-46-101(235)47-39-96)160(270)218-117(72-95-36-44-100(234)45-37-95)153(263)199-89(11)142(252)224-124(81-230)163(273)216-114(68-84(2)3)156(266)205-105(29-21-63-195-176(188)189)148(258)220-120(75-98-79-192-83-198-98)161(271)219-119(74-97-40-48-102(236)49-41-97)159(269)215-116(70-86(6)7)158(268)221-121(76-130(180)238)154(264)202-92(14)173(283)284-140(87(8)9)169(279)226-139(93(15)232)168(278)211-106(30-22-64-196-177(190)191)145(255)207-108(50-55-129(179)237)150(260)204-103(27-19-61-193-174(184)185)146(256)213-113(141(183)251)71-94-34-42-99(233)43-35-94/h34-49,79,83-93,103-128,138-140,230-236H,16-33,50-78,80-82,178,182H2,1-15H3,(H2,179,237)(H2,180,238)(H2,181,239)(H2,183,251)(H,192,198)(H,197,274)(H,199,263)(H,200,265)(H,201,254)(H,202,264)(H,203,240)(H,204,260)(H,205,266)(H,206,272)(H,207,255)(H,208,261)(H,209,275)(H,210,276)(H,211,278)(H,212,277)(H,213,256)(H,214,262)(H,215,269)(H,216,273)(H,217,257)(H,218,270)(H,219,271)(H,220,258)(H,221,268)(H,222,267)(H,223,259)(H,224,252)(H,225,253)(H,226,279)(H,241,242)(H,243,244)(H,245,246)(H,247,248)(H,249,250)(H4,184,185,193)(H4,186,187,194)(H4,188,189,195)(H4,190,191,196)/t88-,89-,90-,91-,92-,93+,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,138-,139-,140-/m0/s1
Standard InChI Key: AMTOVGJPIRDLGT-NGUHXVKZSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 4008.43 | Molecular Weight (Monoisotopic): 4006.0086 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Albertsen L, Andersen JJ, Paulsson JF, Thomsen JK, Norrild JC, Strømgaard K.. (2013) Design and Synthesis of Peptide YY Analogues with C-terminal Backbone Amide-to-Ester Modifications., 4 (12): [PMID:24900634] [10.1021/ml400335g] |
Source(1):